. Author manuscript; available in PMC: 2020 May 7.

Published in final edited form as: Eur Urol Oncol. 2019 Apr 20;3(1):119–127. doi: 10.1016/j.euo.2019.01.008

Table 2 –

Summary of NCI CTCAE grade 3 adverse events occurring in more than one patient

Adverse event	Patient number (n = 60), n (%)
Hypertension	10 (16.7)
Alanine aminotransferase increase	7 (11.7)
Arthralgia	3 (5.0)
Alkaline phosphatase increase	3 (5.0)
Aspartate aminotransferase increase	2 (3.3)
Lymphocyte count decrease	2 (3.3)
Bone pain	2 (3.3)
Hypokalaemia	2 (3.3)
Syncope	2 (3.3)

NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events.